Recently, GenSci announced the official launch of its flagship product, Episil?, now available in China. Through a strategic partnership, Solasia Pharma K.K. granted GenSci exclusive commercialization rights for Episil? in China. As the only clinically validated mucosal protectant with registered clinical trial in China, Episil? brings new hope to cancer patients battling treatment-related oral complications.

Clinical Impacts and Patient Needs
Oral mucositis affects most cancer patients undergoing chemoradiotherapy, leading to severe complications such as mucosal ulceration, persistent pain, and compromised nutritional intake. These challenges frequently result in treatment interruptions, reduced tolerance to anticancer therapies, and diminished quality of life, underscoring the urgent need for effective interventions.

Innovative Benefits of Episil?
Episil?'s advanced formulation quickly forms a protective liquid-crystal film over mucosal wounds within 5 minutes, providing continuous pain relief for up to 8 hours while promoting tissue repair. Its efficacy and safety have been clinically validated, significantly improving patients' ability to maintain oral function and adhere to treatment regimens. This innovation reflects GenSci's commitment to delivering patient-centric solutions that enhance oncology care outcomes.

This breakthrough demonstrates our commitment to developing patient-centric oncology solutions that address critical unmet needs in cancer care. By improving treatment tolerance and quality of life, Episil? empowers patients to remain on course in their fight against cancer.